Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NovoCure LtdNVCR · Entity 4494 | Director | December 02, 2019 | December 04, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NovoCure Ltd
Report date December 02, 2019 · Filed December 04, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 3,359 |
Reported balance
After 2019-12-02 transaction · row 1
1 source rowRow 1 · 2019-12-02 · Sale · Disposed 6,145 · Balance 3,359 F1: On December 2, 2019, Mr. Phillips sold 6,145 shares in multiple trades at prices ranging from $88.09 to $88.27. The price reported above reflects the weighted average sale price. Mr. Phillips hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 2, 2019, Mr. Phillips sold 6,145 shares in multiple trades at prices ranging from $88.09 to $88.27. The price reported above reflects the weighted average sale price. Mr. Phillips hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 02, 2019 Filed Dec 4, 2019 16:23 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 6,145 | $88.11 | $541,448.24 |
DisclosureSEC source: 0001645113-19-000016 · wf-form4_157549456732473.xml · nonDerivative · entry 1 PHILLIPS CHARLES G III · CIK 0001129246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,359 F1 · price: On December 2, 2019, Mr. Phillips sold 6,145 shares in multiple trades at prices ranging from $88.09 to $88.27. The price reported above reflects the weighted average sale price. Mr. Phillips hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 30, 2019 Filed Sep 3, 2019 16:22 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 22,000 | $0.00 Strike: $6.72 | $0.00 |
DisclosureSEC source: 0001209191-19-047959 · doc4.xml · derivative · entry 5 PHILLIPS CHARLES G III · CIK 0001129246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,607 Underlying: Ordinary Shares · 22,000 shares Expires 2022-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| August 30, 2019 Filed Sep 3, 2019 16:22 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 400 | $92.10 | $36,839.20 |
DisclosureSEC source: 0001209191-19-047959 · doc4.xml · nonDerivative · entry 4 PHILLIPS CHARLES G III · CIK 0001129246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,504 F3 · price: On August 30, 2019, Mr. Phillips sold 400 shares in multiple trades at prices ranging from $91.95 to $92.27. The price reported above reflects the weighted average sale price. Mr. Phillips hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 30, 2019 Filed Sep 3, 2019 16:22 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 12,908 | $91.46 | $1,180,539.86 |
DisclosureSEC source: 0001209191-19-047959 · doc4.xml · nonDerivative · entry 3 PHILLIPS CHARLES G III · CIK 0001129246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,904 F2 · price: On August 30, 2019, Mr. Phillips sold 12,908 shares in multiple trades at prices ranging from $90.93 to $91.92. The price reported above reflects the weighted average sale price. Mr. Phillips hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 30, 2019 Filed Sep 3, 2019 16:22 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 8,692 | $90.63 | $787,738.58 |
DisclosureSEC source: 0001209191-19-047959 · doc4.xml · nonDerivative · entry 2 PHILLIPS CHARLES G III · CIK 0001129246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,812 F1 · price: On August 30, 2019, Mr. Phillips sold 8,692 shares in multiple trades at prices ranging from $89.92 to $90.91. The price reported above reflects the weighted average sale price. Mr. Phillips hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 30, 2019 Filed Sep 3, 2019 16:22 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 22,000 | $6.72 | $147,840.00 |
DisclosureSEC source: 0001209191-19-047959 · doc4.xml · nonDerivative · entry 1 PHILLIPS CHARLES G III · CIK 0001129246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,504 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 29, 2019 Filed May 31, 2019 16:11 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 23,600 | $0.00 Strike: $12.30 | $0.00 |
DisclosureSEC source: 0001209191-19-033629 · doc4.xml · derivative · entry 12 PHILLIPS CHARLES G III · CIK 0001129246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 23,600 shares Expires 2027-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 29, 2019 Filed May 31, 2019 16:11 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 21,500 | $0.00 Strike: $11.39 | $0.00 |
DisclosureSEC source: 0001209191-19-033629 · doc4.xml · derivative · entry 11 PHILLIPS CHARLES G III · CIK 0001129246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 21,500 shares Expires 2026-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 29, 2019 Filed May 31, 2019 16:11 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 50,000 | $0.00 Strike: $6.72 | $0.00 |
DisclosureSEC source: 0001209191-19-033629 · doc4.xml · derivative · entry 10 PHILLIPS CHARLES G III · CIK 0001129246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,607 Underlying: Ordinary Shares · 50,000 shares Expires 2022-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Options to buy 50,000 ordinary shares are vested and currently exercisable as of the date hereof. Read SEC document |
| May 29, 2019 Filed May 31, 2019 16:11 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,400 | $52.82 | $73,949.40 |
DisclosureSEC source: 0001209191-19-033629 · doc4.xml · nonDerivative · entry 9 PHILLIPS CHARLES G III · CIK 0001129246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,504 F6 · price: On May 29, 2019, Mr. Phillips sold 1,400 shares in multiple trades at prices ranging from $52.63 to $52.96. The price reported above reflects the weighted average sale price. Mr. Phillips hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 29, 2019 Filed May 31, 2019 16:11 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 22,200 | $52.08 | $1,156,264.80 |
DisclosureSEC source: 0001209191-19-033629 · doc4.xml · nonDerivative · entry 8 PHILLIPS CHARLES G III · CIK 0001129246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,904 F5 · price: On May 29, 2019, Mr. Phillips sold 22,200 shares in multiple trades at prices ranging from $51.63 to $52.61. The price reported above reflects the weighted average sale price. Mr. Phillips hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 29, 2019 Filed May 31, 2019 16:11 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 23,600 | $12.30 | $290,280.00 |
DisclosureSEC source: 0001209191-19-033629 · doc4.xml · nonDerivative · entry 7 PHILLIPS CHARLES G III · CIK 0001129246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,104 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 29, 2019 Filed May 31, 2019 16:11 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 5,174 | $52.96 | $274,020.21 |
DisclosureSEC source: 0001209191-19-033629 · doc4.xml · nonDerivative · entry 6 PHILLIPS CHARLES G III · CIK 0001129246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,504 F4 · price: On May 29, 2019, Mr. Phillips sold 5,174 shares in multiple trades at prices ranging from $52.58 to $53.30. The price reported above reflects the weighted average sale price. Mr. Phillips hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 29, 2019 Filed May 31, 2019 16:11 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 16,326 | $52.09 | $850,356.04 |
DisclosureSEC source: 0001209191-19-033629 · doc4.xml · nonDerivative · entry 5 PHILLIPS CHARLES G III · CIK 0001129246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,678 F3 · price: On May 29, 2019, Mr. Phillips sold 16,326 shares in multiple trades at prices ranging from $51.57 to $52.56. The price reported above reflects the weighted average sale price. Mr. Phillips hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 29, 2019 Filed May 31, 2019 16:11 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 21,500 | $11.39 | $244,885.00 |
DisclosureSEC source: 0001209191-19-033629 · doc4.xml · nonDerivative · entry 4 PHILLIPS CHARLES G III · CIK 0001129246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,004 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 29, 2019 Filed May 31, 2019 16:11 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,920 | $52.84 | $154,304.48 |
DisclosureSEC source: 0001209191-19-033629 · doc4.xml · nonDerivative · entry 3 PHILLIPS CHARLES G III · CIK 0001129246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,504 F2 · price: On May 29, 2019, Mr. Phillips sold 2,920 shares in multiple trades at prices ranging from $52.64 to $53.06. The price reported above reflects the weighted average sale price. Mr. Phillips hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 29, 2019 Filed May 31, 2019 16:11 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 47,080 | $52.09 | $2,452,303.04 |
DisclosureSEC source: 0001209191-19-033629 · doc4.xml · nonDerivative · entry 2 PHILLIPS CHARLES G III · CIK 0001129246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,424 F1 · price: On May 29, 2019, Mr. Phillips sold 47,080 shares in multiple trades at prices ranging from $51.62 to $52.61. The price reported above reflects the weighted average sale price. Mr. Phillips hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 29, 2019 Filed May 31, 2019 16:11 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 50,000 | $6.72 | $336,000.00 |
DisclosureSEC source: 0001209191-19-033629 · doc4.xml · nonDerivative · entry 1 PHILLIPS CHARLES G III · CIK 0001129246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,504 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 22, 2019 Filed May 24, 2019 16:14 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 6,340 | $0.00 Strike: $56.36 | $0.00 |
DisclosureSEC source: 0001209191-19-032689 · doc4.xml · derivative · entry 2 PHILLIPS CHARLES G III · CIK 0001129246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,340 Underlying: Ordinary Shares · 6,340 shares Expires 2029-05-22 F2 · derivative.exercise_date: Options to buy 6,340 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2020 annual general meeting of shareholders. Read SEC document |
| May 22, 2019 Filed May 24, 2019 16:14 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantRestricted Stock Units | 3,359 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-032689 · doc4.xml · nonDerivative · entry 1 PHILLIPS CHARLES G III · CIK 0001129246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,504 F1 · shares: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2020 annual general meeting of shareholders. Read SEC document |
| May 21, 2019 Filed May 22, 2019 16:24 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Unit · Derivative | 6,145 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-032052 · doc4.xml · derivative · entry 2 PHILLIPS CHARLES G III · CIK 0001129246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,145 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| May 21, 2019 Filed May 22, 2019 16:24 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 6,145 | $48.87 | $300,306.15 |
DisclosureSEC source: 0001209191-19-032052 · doc4.xml · nonDerivative · entry 1 PHILLIPS CHARLES G III · CIK 0001129246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,145 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 20:08 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantRestricted Stock Unit · Derivative | 6,145 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-035380 · doc4.xml · derivative · entry 2 PHILLIPS CHARLES G III · CIK 0001129246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,145 Underlying: Ordinary Shares · 6,145 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one (1) ordinary share. F3 · derivative.exercise_date: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2019 annual general meeting of shareholders. F3 · derivative.expiration_date: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2019 annual general meeting of shareholders. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 20:08 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 12,345 | $0.00 Strike: $31.45 | $0.00 |
DisclosureSEC source: 0001209191-18-035380 · doc4.xml · derivative · entry 1 PHILLIPS CHARLES G III · CIK 0001129246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,345 Underlying: Ordinary Shares · 12,345 shares Expires 2028-05-31 F1 · derivative.exercise_date: Options to buy 12,345 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2019 annual general meeting of shareholders. Read SEC document |
| May 25, 2018 Filed May 30, 2018 18:01 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 50,000 | $0.00 Strike: $6.72 | $0.00 |
DisclosureSEC source: 0001209191-18-034229 · doc4.xml · derivative · entry 3 PHILLIPS CHARLES G III · CIK 0001129246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,607 Underlying: Ordinary Shares · 50,000 shares Expires 2022-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Options to buy 50,000 ordinary shares are vested and currently exercisable as of the date hereof. Read SEC document |
| May 25, 2018 Filed May 30, 2018 18:01 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 50,000 | $30.30 | $1,515,075.00 |
DisclosureSEC source: 0001209191-18-034229 · doc4.xml · nonDerivative · entry 2 PHILLIPS CHARLES G III · CIK 0001129246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: On May 25, 2018, Mr. Phillips sold 50,000 shares in multiple trades at prices ranging from $30.125 to $30.625. The price reported above reflects the weighted average sale price. Mr. Phillips hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 25, 2018 Filed May 30, 2018 18:01 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 50,000 | $6.72 | $336,000.00 |
DisclosureSEC source: 0001209191-18-034229 · doc4.xml · nonDerivative · entry 1 PHILLIPS CHARLES G III · CIK 0001129246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2017 Filed May 12, 2017 16:50 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 23,600 | $0.00 Strike: $12.30 | $0.00 |
DisclosureSEC source: 0001209191-17-032019 · doc4.xml · derivative · entry 1 PHILLIPS CHARLES G III · CIK 0001129246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,600 Underlying: Ordinary Shares · 23,600 shares Expires 2027-05-10 F1 · derivative.exercise_date: Options to buy 23,600 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the date of the Company's 2018 annual general meeting of shareholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.